Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD Trial for Patients with Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (1)

 Boehringer Ingelheim Reports Results of OFEV (nintedanib) in P-III INBUILD Trial for Patients with Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (1)

Interpace Diagnostics Signs an AI-Driven Agreement with Predictive Oncology for Diagnosing Thyroid Cancer

Shots:

  • The P-III INBUILD trial involves assessing of OFEV vs PBO in patients with chronic fibrosing interstitial lung disease (ILDs) with signs of progression for 52 wks.
  • P-III INBUILD study results: met its 1EPs, slowed lung function decline by 57%, adjusted annual rate of decline in FVC @52 wks. (-80.8 mL/year vs -187.8 mL/year). Ofev showed consistent effect on lung function decline in patients with UIP like fibrotic pattern and those with other fibrotic patterns on HRCT, consistent safety profile as found in IPF and SSc-ILD patients
  • Ofev (nintedanib) is a tyrosine kinase inhibitor approved in 70+ countries including the US, EU and Japan for the treatment of patients living with idiopathic pulmonary fibrosis (IPF)   

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post